The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation.
 
Colin R Lindsay
Honoraria - Amgen
Consulting or Advisory Role - Amgen; cbpartners
Research Funding - Revolution Medicines (Inst)
(OPTIONAL) Uncompensated Relationships - Amgen; Amgen
 
Rajwanth Veluswamy
Honoraria - AstraZeneca; BeiGene; Boehringer Ingelheim; G1 Therapeutics; Merus; Novocure; Regeneron
Consulting or Advisory Role - AstraZeneca; BerGenBio; Boehringer Ingelheim; G1 Therapeutics; Merus; Novartis; Novocure; Regeneron
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Onconova Therapeutics
Travel, Accommodations, Expenses - Boehringer Ingelheim; Regeneron
 
Gilberto Castro
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Libbs; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi; Takeda; Yuhan
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche
 
Daniel Shao-Weng Tan
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; C4 Therapeutics; Loxo; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Rafael Caparica
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Sabine Glaser
Employment - Novartis
Stock and Other Ownership Interests - Alcon; Novartis
 
Shweta Malhotra
Stock and Other Ownership Interests - Novartis
 
Aislyn Boran
Employment - Daiichi Sankyo; Novartis
Stock and Other Ownership Interests - Daiichi Sankyo; Novartis; TetraLogic Pharmaceuticals
Travel, Accommodations, Expenses - Novartis
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BerGenBio; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; F. Hoffmann LaRoche; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; F. Hoffmann LaRoche; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; Touch Oncology
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRIFOLS